Thrombolytic activity of defibrotide against old venous thrombi.

Abstract:

:The age of the thrombus is probably a very important determinant of the outcome of thrombolysis. The clinical potential for rapidly dissolving thrombi by thrombolytic therapy is considerable because restoration of the blood flow can rescue the jeopardized district served by the occluded vessel such as for myocardial infarction, deep vein thrombosis, arterial thrombosis, pulmonary embolism, and occlusion of retinal vessels. Defibrotide was effective against 3-, 7-, or 10-day-old thrombi; its ED50s were 32, 65, or 118 mg/kg-1 hour-1, respectively, suggesting that the age of the thrombus could play a role in the outcome of thrombolysis. A similar pattern was also shown for urokinase.

journal_name

Semin Thromb Hemost

authors

Niada R,Porta R,Pescador R,Mantovani M,Prino G

doi

10.1055/s-2007-1002747

subject

Has Abstract

pub_date

1989-10-01 00:00:00

pages

474-9

issue

4

eissn

0094-6176

issn

1098-9064

journal_volume

15

pub_type

杂志文章
  • Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience.

    abstract::Natural inhibitors of coagulation, in other words, antithrombin (AT), the protein C system, and tissue factor pathway inhibitor (TFPI), play an important role in controlling the activation of coagulation during disseminated intravascular coagulation (DIC). Furthermore, they may not only influence coagulation but also ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2001-18871

    authors: de Jonge E,van der Poll T,Kesecioglu J,Levi M

    更新日期:2001-12-01 00:00:00

  • Experimental and clinical validation of the prophylactic antithrombotic effects of a low molecular weight heparin (enoxaparin).

    abstract::Several LMWHs are currently available for commercial use. The development status of each of these products in the area of prophylaxis, therapeutics, and other indications is given in Table 4. Enoxaparin and Fraxiparin appear to be the most developed LMWHs in both the surgical and medical areas. Many well-designed clin...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:

    authors: Fareed J,Walenga JM,Hoppensteadt D,Borris LC,Lassen MR

    更新日期:1991-01-01 00:00:00

  • Anagrelide treatment in myeloproliferative disorders.

    abstract::Platelet-lowering therapy in myeloproliferative disorders includes cytostatic drugs, mainly hydroxyurea, interferon alpha, and anagrelide. Anagrelide is the latest addition to the therapeutic arsenal, and the basis for its use is reviewed. The platelet-lowering efficacy is 70 to 80% in essential thrombocythemia, and t...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2006-939437

    authors: Birgegard G

    更新日期:2006-04-01 00:00:00

  • New developments in lung endothelial heterogeneity: Von Willebrand factor, P-selectin, and the Weibel-Palade body.

    abstract::Quiescent pulmonary endothelium establishes an antithrombotic, anti-inflammatory surface that promotes blood flow. However, the endothelium rapidly responds to injury and inflammation by promoting thrombosis and enabling the directed transmigration of inflammatory cells, such as neutrophils, into the alveolar airspace...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0030-1253452

    authors: Ochoa CD,Wu S,Stevens T

    更新日期:2010-04-01 00:00:00

  • Recent Advances in the Molecular Imaging of Atherosclerosis.

    abstract::Atherosclerosis is the major underlying cause of cardiovascular diseases, the prevalence of which is continuously increasing, thus currently standing as the leading global cause of death. This pathology gradually develops over the course of 50 or more years throughout the life of an individual under the influence of a...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0039-1701019

    authors: Larivière M,Bonnet S,Lorenzato C,Laroche-Traineau J,Ottonès F,Jacobin-Valat MJ,Clofent-Sanchez G

    更新日期:2020-07-01 00:00:00

  • Anticardiolipin beta2-glycoprotein I antibody: is a high titer related to unfavorable pregnancy outcome?

    abstract::We present the clinical characteristics of pregnancy histories and subsequent pregnancy outcomes of 13 women who tested positive for anticardiolipin beta2-glycoprotein I antibody (aCLbeta2GPI). Six of the 13 women had a history of recurrent spontaneous abortion (RSA). The prevalence of aCLbeta2GPI syndrome among women...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2004-815631

    authors: Yamada H,Kato EH,Morikawa M,Shimada S,Ebina Y,Sakuragi N,Suzuki S,Minakami H

    更新日期:2003-12-01 00:00:00

  • New insights into the role of erythrocytes in thrombus formation.

    abstract::The role of erythrocytes in thrombus formation has previously been regarded as passive by their influence on rheology. Erythrocytes are known, due to their abundance and size, to push platelets to the vascular wall (laminar shearing). This results in an increased platelet delivery at the vascular wall enabling platele...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0033-1363470

    authors: Du VX,Huskens D,Maas C,Al Dieri R,de Groot PG,de Laat B

    更新日期:2014-02-01 00:00:00

  • Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents.

    abstract::Development of inhibitory antibodies (inhibitors) to factor VIII (FVIII) is the most serious adverse event in replacement therapy of hemophilia A patients. The etiology and management of this condition remain major challenges for both researchers and clinicians. In the present review, we discuss recent advances in und...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0029-1245106

    authors: Ananyeva NM,Lee TK,Jain N,Shima M,Saenko EL

    更新日期:2009-11-01 00:00:00

  • The role of individual risk factors in anticoagulant-associated hemorrhages.

    abstract::Hemorrhagic complications during therapy with anticoagulant drugs have long been considered as simply and directly related to overdosage. Yet, such adverse events have also been observed in patients correctly anticoagulated, i.e., within the therapeutic range, thus demonstrating that the predictive value of laboratory...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:

    authors: Toulemonde F

    更新日期:1996-01-01 00:00:00

  • Occurrence of AIDS in hemophiliacs in Japan.

    abstract::This report describes the first two Japanese cases of AIDS developed in patients with hemophilia. One was a 48-year-old man with hemophilia B and the other was a 62-year-old patient with hemophilia A. They had nonspecific prodromal syndromes of AIDS initially, and later developed fatal opportunistic infections with Ca...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-1004393

    authors: Abe T,Kazama M,Kinoshita T,Matuda J,Yoshimura Y,Ryu T,Takahashi I

    更新日期:1985-10-01 00:00:00

  • Using Artificial Intelligence to Manage Thrombosis Research, Diagnosis, and Clinical Management.

    abstract::Thrombosis development in either arterial or venous system remains a major cause of death and disability worldwide. This poorly controlled in vivo clotting could result in many severe complications including myocardial infarction, venous thromboembolism, stroke, and cerebral venous thrombosis, to name a few. These con...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0039-1697949

    authors: Mishra A,Ashraf MZ

    更新日期:2020-06-01 00:00:00

  • The multiple organ dysfunction syndrome in cancer patients undergoing hematopoietic stem cell transplantation.

    abstract::In the past two decades, major improvements in antibiotics and other elements of supportive care have decreased the number and severity of complications of hematopoietic stem cell transplantation (HSCT). Despite these improvements, many subpopulations of transplant patients still have a significant morbidity and morta...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-994924

    authors: Haire WD

    更新日期:1999-01-01 00:00:00

  • ABO blood group and vascular disease: an update.

    abstract::It has been well known for many years that the ABO blood group has a major influence on hemostasis, through its influence on von Willebrand factor and, consequently, factor VIII plasma levels. Although the relationship between non-O blood type and the risk of venous thromboembolism is nowadays also well established, t...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,meta分析,评审

    doi:10.1055/s-0033-1363460

    authors: Dentali F,Sironi AP,Ageno W,Crestani S,Franchini M

    更新日期:2014-02-01 00:00:00

  • Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin.

    abstract::A prospective randomized double-blind trial was performed comparing conventional low-dose heparin with a LMWH fragment (Kabi 2165, Fragmin) for thromboprophylaxis in elective general abdominal surgical patients. The first dose of the fragment was given in the evening before surgery, and thereafter every evening. There...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Bergqvist D,Burmark US,Frisell J,Guilbaud O,Hallböök T,Horn A,Lindhagen A,Ljungner H,Ljungström KG,Mätzsch T

    更新日期:1990-10-01 00:00:00

  • Management of oral anticoagulant treatment in patients with venous thromboembolism.

    abstract::Oral anticoagulants (OAs) are the drugs of choice for the prevention of recurrence and death in patients with venous thromboembolism (VTE). Oral anticoagulant treatment (OAT) aims to retard blood coagulation to obtain maximum protection against thromboembolic events with the lowest risk of bleeding. The intensity of O...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2006-955460

    authors: Pengo V

    更新日期:2006-11-01 00:00:00

  • Travel, venous thromboembolism, and thrombophilia.

    abstract::Current evidence indicates that prolonged air travel predisposes to venous thrombosis and pulmonary embolism. An effect is seen once travel duration exceeds 6 to 9 hours and becomes obvious in long-haul passengers traveling for 12 or more hours. A recent records linkage study found that increase in thrombosis rate amo...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2005-863810

    authors: Gallus AS

    更新日期:2005-02-01 00:00:00

  • Preventing or Eradicating Factor VIII Antibody Formation in Patients with Hemophilia A: What Can We Learn from Other Disorders?

    abstract::Eradication of factor VIII (FVIII) specific neutralizing antibodies (also known as inhibitors) by the traditional method of immune tolerance induction (ITI) is costly and unsuccessful in one out of three patients. Furthermore, effective inhibitor prevention strategies are presently lacking. An overview is given in thi...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0038-1666823

    authors: Hassan S,Fijnvandraat K,van der Bom JG,Gouw SC

    更新日期:2018-09-01 00:00:00

  • DNA sequence analysis of protein S deficiency--identification of four point mutations in twelve Japanese subjects.

    abstract::The molecular basis for the hereditary type I protein S (PS) deficiency was investigated. DNA sequence analysis of 12 patients with PS deficiency in Japan identified four point mutations and three of them were novel. Nonsense mutations found in two unrelated patients resulted in termination of the PS polypeptide chain...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2001-14075

    authors: Iwaki T,Mastushita T,Kobayashi T,Yamamoto Y,Nomura Y,Kagami K,Nakayama T,Sugiura I,Kojima T,Takamatsu J,Kanayama N,Saito H

    更新日期:2001-01-01 00:00:00

  • Hemostatic Efficacy of Pathogen-Inactivated Blood Components.

    abstract::Pathogen inactivation (PI), or pathogen reduction technology, reduces the infectious risk of plasma and platelet transfusions, and also affects clotting factor activities and platelet viabilities. Plasma is treated with solvent-detergent to disrupt enveloped viruses, or with photoactive agents methylene blue plus ligh...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0035-1564845

    authors: Ramsey G

    更新日期:2016-03-01 00:00:00

  • Use of D-dimer assays in the diagnosis of venous thrombosis.

    abstract::In the course of fibrin formation, the D-domains of adjacent fibrin molecules within the fibrin polymer are covalently linked by factor XIIIa, leading to the formation of a D-domain dimer. Proteolysis of this cross-linked fibrin generates fibrin fragments D-dimer and E as terminal products. Fragment D-dimer therefore ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2000-13221

    authors: Dempfle CE

    更新日期:2000-01-01 00:00:00

  • Identification of p.W246L as a novel mutation in the GP1BA gene responsible for platelet-type von Willebrand disease.

    abstract::Platelet-type von Willebrand disease (PT-VWD) and type 2B von Willebrand disease (2B-VWD) are rare bleeding disorders characterized by increased ristocetin-induced platelet aggregation (RIPA) at low concentrations of ristocetin. Diagnosis of either condition is not easy and the differential diagnosis between the two e...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0033-1364183

    authors: Woods AI,Sanchez-Luceros A,Bermejo E,Paiva J,Alberto MF,Grosso SH,Kempfer AC,Lazzari MA

    更新日期:2014-03-01 00:00:00

  • Plasminogen activator inhibitor-1 in aging.

    abstract::Plasminogen activator inhibitor-1 (PAI-1), a principal inhibitor of fibrinolysis, is induced in thrombotic, fibrotic, and cardiovascular diseases, which in turn primarily afflict the older population. This induction of PAI-1 may play an important role in the pathology of these diseases as PAI-1 can regulate the dissol...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0034-1384635

    authors: Yamamoto K,Takeshita K,Saito H

    更新日期:2014-09-01 00:00:00

  • Prognostic Scores for Acute Pulmonary Embolism.

    abstract::Rapid and accurate risk stratification is critical in determining the optimal treatment strategy for patients with acute pulmonary embolism (PE). Early identification of patients with normal blood pressure and a favorable prognosis (low-risk PE) might select a subset of patients for outpatient treatment, which is asso...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0036-1597287

    authors: Morillo R,Moores L,Jiménez D

    更新日期:2017-07-01 00:00:00

  • Noninvasive plaque imaging using multislice detector spiral computed tomography.

    abstract::Multislice detector spiral computed tomography (MSCT) is a noninvasive modality for visualization and evaluation of atherosclerosis in vivo in different arterial beds. Rapid technical advances led to a significant improvement of the diagnostic accuracy of coronary MSCT angiography. The most popular clinical applicatio...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-969035

    authors: Schroeder S,Kopp AF,Burgstahler C

    更新日期:2007-03-01 00:00:00

  • To mix or not to mix in lupus anticoagulant testing? That is the question.

    abstract::Mixing patient and normal plasma has been used for many years to assist with making decisions on which direction to proceed for further investigation of abnormally prolonged coagulation tests, namely, either individual coagulation factor measurement or the search for circulating anticoagulants. Mixing tests, however, ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0032-1304717

    authors: Tripodi A

    更新日期:2012-06-01 00:00:00

  • Welcome to Seminars in Thrombosis and Hemostasis 2019-New (2017) Impact Factor and Most Highly Cited Papers.

    abstract:: ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 社论,历史文章

    doi:10.1055/s-0038-1677460

    authors: Favaloro EJ

    更新日期:2019-02-01 00:00:00

  • Molecular mechanisms of megakaryocyte differentiation.

    abstract::Each bone marrow megakaryocyte (MK) releases thousands of platelets into the circulation, and the underlying molecular and cellular mechanisms recently have received intense scrutiny. Genetic studies are beginning to clarify the mechanisms by which transcription factors help distinguish MK progenitors from other blood...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2004-833474

    authors: Schulze H,Shivdasani RA

    更新日期:2004-08-01 00:00:00

  • Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.

    abstract::In order to assess inhibitor development in previously untreated patients (PUPs) with severe (factor VIII [FVIII]<1%) and moderate (FVIII 1 to 5%) hemophilia A, a prospective study was initiated in 1976. During the 23-year study period, 72 hemophiliacs were frequently exposed prophylactically or on demand to plasma-de...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2002-32664

    authors: Kreuz W,Ettingshausen CE,Zyschka A,Oldenburg J,Saguer IM,Ehrenforth S,Klingebiel T

    更新日期:2002-06-01 00:00:00

  • Change in protein phenotype without a nucleus: translational control in platelets.

    abstract::For most cells the nucleus takes center stage. Not only is it the largest organelle in eukaryotic cells, it carries most of the genome and transcription of DNA to RNA largely takes place in the nucleus. Because transcription is a major step in gene regulation, the absence of a nucleus is limiting from a biosynthetic s...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2004-833484

    authors: Weyrich AS,Lindemann S,Tolley ND,Kraiss LW,Dixon DA,Mahoney TM,Prescott SP,McIntyre TM,Zimmerman GA

    更新日期:2004-08-01 00:00:00

  • Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin.

    abstract::Site-directed thrombin inhibitors are being currently assessed clinically for their antithrombotic efficacy. Although these agents are claimed to be specific and direct thrombin inhibitors, their mechanism of inhibition varies. The objective of these studies was to compare four such agents in in vitro systems and to a...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-1000393

    authors: Callas DD,Hoppensteadt D,Fareed J

    更新日期:1995-01-01 00:00:00